Phillip Md Et Al Frost Purchases 1,800 Shares of Opko Health Inc. (OPK) Stock

Opko Health Inc. (NYSE:OPK) CEO Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock in a transaction on Tuesday, October 18th. The shares were purchased at an average price of $9.29 per share, for a total transaction of $16,722.00. Following the completion of the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $28,510,554.79. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, October 17th, Phillip Md Et Al Frost acquired 3,600 shares of Opko Health stock. The shares were purchased at an average price of $9.34 per share, for a total transaction of $33,624.00.
  • On Friday, October 14th, Phillip Md Et Al Frost acquired 1,800 shares of Opko Health stock. The shares were purchased at an average price of $9.48 per share, for a total transaction of $17,064.00.
  • On Thursday, October 13th, Phillip Md Et Al Frost acquired 5,400 shares of Opko Health stock. The shares were purchased at an average price of $9.52 per share, for a total transaction of $51,408.00.
  • On Tuesday, October 11th, Phillip Md Et Al Frost acquired 7,200 shares of Opko Health stock. The shares were purchased at an average price of $9.78 per share, for a total transaction of $70,416.00.
  • On Monday, October 10th, Phillip Md Et Al Frost acquired 24,800 shares of Opko Health stock. The shares were purchased at an average price of $9.82 per share, for a total transaction of $243,536.00.
  • On Thursday, October 6th, Phillip Md Et Al Frost acquired 4,200 shares of Opko Health stock. The shares were purchased at an average price of $10.53 per share, for a total transaction of $44,226.00.
  • On Tuesday, October 4th, Phillip Md Et Al Frost acquired 3,600 shares of Opko Health stock. The shares were purchased at an average price of $10.57 per share, for a total transaction of $38,052.00.
  • On Friday, September 30th, Phillip Md Et Al Frost purchased 1,800 shares of Opko Health stock. The stock was bought at an average price of $10.54 per share, for a total transaction of $18,972.00.
  • On Thursday, September 29th, Phillip Md Et Al Frost purchased 3,600 shares of Opko Health stock. The stock was bought at an average price of $10.67 per share, for a total transaction of $38,412.00.
  • On Wednesday, September 28th, Phillip Md Et Al Frost purchased 5,400 shares of Opko Health stock. The stock was bought at an average price of $11.01 per share, for a total transaction of $59,454.00.

Opko Health Inc. (NYSE:OPK) traded down 1.38% on Wednesday, reaching $9.27. 1,812,516 shares of the company’s stock traded hands. The firm’s 50-day moving average is $10.09 and its 200 day moving average is $10.05. The firm has a market cap of $5.10 billion and a PE ratio of 38.79. Opko Health Inc. has a 12 month low of $7.12 and a 12 month high of $11.85.

Opko Health (NYSE:OPK) last announced its quarterly earnings results on Monday, August 8th. The company reported $0.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.05. The company had revenue of $357.10 million for the quarter, compared to the consensus estimate of $324.11 million. During the same quarter in the prior year, the company earned ($0.09) earnings per share. The company’s quarterly revenue was up 742.2% on a year-over-year basis. Equities analysts predict that Opko Health Inc. will post ($0.05) EPS for the current year.

Insider Buying and Selling by Quarter for Opko Health (NYSE:OPK)

A number of equities research analysts have recently weighed in on the stock. Oppenheimer Holdings Inc. restated an “outperform” rating on shares of Opko Health in a research note on Saturday, June 25th. JPMorgan Chase & Co. set a $14.00 price target on shares of Opko Health and gave the company a “buy” rating in a research note on Tuesday, August 9th. Jefferies Group restated a “hold” rating and issued a $10.00 price target on shares of Opko Health in a research note on Monday, October 10th. Zacks Investment Research upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th. Finally, Standpoint Research raised their price target on shares of Opko Health from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, June 21st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Opko Health currently has an average rating of “Buy” and an average price target of $13.20.

Large investors have recently made changes to their positions in the stock. Janus Capital Management LLC boosted its stake in shares of Opko Health by 0.6% in the second quarter. Janus Capital Management LLC now owns 15,800 shares of the company’s stock valued at $148,000 after buying an additional 100 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its position in Opko Health by 1.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 22,945 shares of the company’s stock valued at $214,000 after buying an additional 261 shares during the period. Gilman Hill Asset Management LLC boosted its position in Opko Health by 0.6% in the second quarter. Gilman Hill Asset Management LLC now owns 46,661 shares of the company’s stock valued at $436,000 after buying an additional 298 shares during the period. Fisher Asset Management LLC boosted its position in Opko Health by 1.1% in the third quarter. Fisher Asset Management LLC now owns 38,229 shares of the company’s stock valued at $405,000 after buying an additional 403 shares during the period. Finally, Capstone Asset Management Co. boosted its position in Opko Health by 3.3% in the third quarter. Capstone Asset Management Co. now owns 16,216 shares of the company’s stock valued at $172,000 after buying an additional 520 shares during the period.

About Opko Health

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NYSE:OPK

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

GoPro Planning to Cut 200 Jobs
GoPro Planning to Cut 200 Jobs
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Early Data from Cyber Monday Shows Sales Increasing Over 9%
Retailers Anticipating Strong Support for Small Business Saturday
Retailers Anticipating Strong Support for Small Business Saturday
Eli Lilly Alzheimer’s Drug Does Not Pass the Test
Eli Lilly Alzheimer’s Drug Does Not Pass the Test
Disney to Build Larger Hong Kong Kingdom
Disney to Build Larger Hong Kong Kingdom
DraftKings and FanDuel Finally Will Merge
DraftKings and FanDuel Finally Will Merge


 
© 2006-2016 Ticker Report. Google+.